IGF2

Across TCGA pan-cancer cohorts, IGF2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGF2 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGF2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated IGF2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, CESC, and LUAD are the cancer types where IGF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.376	.024	24	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
LUAD	OS	Median	All	0.408	0.687	.022	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGF2–STAD (DFS)

Open the STAD breakdown →